Breaking News, Financial News

Financial Reports: Charles River 1Q

Preclinical revenues drop, offset by RMS uptick

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Charles River Laboratories 1Q12

1Q Revenues: $286 million (flat)

1Q Earnings: $26 million (-16%)

Comments: Research Models and Services was up 6% to $183 million, driven by In Vitro and Avian businesses., for its best quarter since 2008. Preclinical Services dropped 9% to $103 million, with lower sales of biopharmaceutical services due to typically slow starts from large biopharma cients.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters